Sodium 2-(5-bromopyrimidin-2-yl)acetate

Catalog No. :
ACQVRA845
CAS No. :
2055841-00-2
Molecular Formula :
C6H4BrN2NaO2
Molecular Weight :
239.00

IUPAC Name:Sodium 2-(5-bromopyrimidin-2-yl)acetate

Sodium 2-(5-bromopyrimidin-2-yl)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
500mg95%$81.00Login to see priceIn stockIn stock
1g95%$120.00Login to see priceIn stockIn stock
5g95%$380.00Login to see priceInquiryInquiry
10g95%$633.00Login to see priceInquiryInquiry
25g95%$1264.00Login to see priceInquiryInquiry
50g95%$2023.00Login to see priceInquiryInquiry
100g95%$3287.00Login to see priceInquiryInquiry
250g95%$6572.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameSodium 2-(5-bromopyrimidin-2-yl)acetate
IUPAC NameSodium 2-(5-bromopyrimidin-2-yl)acetate
MDL No.MFCD30531336
Molecular FormulaC6H4BrN2NaO2
Molecular Weight239.00
SMILESO=C([O-])CC1=NC=C(Br)C=N1.[Na+]
InChI KeyDEHNCPQTCAVCDJ-UHFFFAOYSA-M
Synonymsodium 2-(5-bromopyrimidin-2-yl)acetate;2-Pyrimidineacetic acid, 5-bromo-, sodium salt (1:1);sodium salt - [B84580]
CAS No.2055841-00-2
PubChem CID127264214

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACQVRA845 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGFLC029 route compound structure diagram
    ACGFLC0291134327-91-5 In Stock
  2. Then
  3. ACQVRA845 route product structure diagram
    ACQVRA8452055841-00-2 In Stock
Inquiry

2. ACQVRA845 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIBHE310 route compound structure diagram
    ACIBHE310948594-80-7 In Stock
  2. Then
  3. ACQVRA845 route product structure diagram
    ACQVRA8452055841-00-2 In Stock
Inquiry

Comments (0)